chromium has been researched along with Ovarian Neoplasms in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (65.71) | 18.7374 |
| 1990's | 7 (20.00) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y | 1 |
| Kulbacka, J; Piwowar, A; Roik, J; Saczko, J; Sawicka, E | 1 |
| Bristow, RE; Diaz-Montes, TP; Giuntoli, RL; Oelke, M; Rogers, O; Webb, TJ; Zoso, A | 1 |
| ARIEL, IM | 1 |
| Foley, RJ; Harris, K; Jama, Y; Mittendorf, EA; Peoples, GE; Ponniah, S; Shriver, CD; Storrer, CE | 1 |
| Bakshi, S; Barlow, JJ; Bender, MA; Lele, SB; Parthasarathy, KL; Piver, MS | 1 |
| Bakri, YN; Given, FT | 1 |
| Carlson, JA; Jose, B; Osborne, RP; Sharma, SC | 2 |
| Kirchner, AB; Powell, JL | 1 |
| Creasman, WT; Currie, JL; Harris, CC; Sullivan, DC; Wilkinson, RH | 1 |
| Adelstein, SJ; Bloomer, WD; Gordon, PR; McLaughlin, WH; Neirinckx, RD; Ruth, TJ; Wolf, AP | 1 |
| Backx, C; Cash, SA; Durand, RE; Leichner, PK | 1 |
| Blessing, J; Creasman, WT; Disaia, PJ; Johnston, W; Weed, JC; Wilkinson, RH | 1 |
| Leibel, SA; Leichner, PK; Order, SE; Rosenshein, NB | 1 |
| Chapman, L; Fanning, J; Hilgers, RD; Meyers, W | 1 |
| Billings, PC; Engelsberg, BN; Johnson, SW; Merrick, WC; Rozmiarek, H; Wang, JF; Witmer, C | 1 |
| Alfonso-De Matte, MY; Kruk, PA; Moses-Soto, H | 1 |
| Gruber, H; Lifshitz, SG; Tewfik, FA; Tewfik, HH | 1 |
| Cain, JM; Lee, RB; Peters, WA; Smith, MR; Yon, JL | 1 |
| Berchuck, A; Clarke-Pearson, DL; Dodge, R; Soper, JT | 1 |
| Berchuck, A; Clarke-Pearson, DL; Soper, JT | 1 |
| Rubinstein, L; Walton, LA; Yadusky, A | 1 |
| Barnhill, D; Doering, D; Park, R; Proctor, J | 1 |
| Austin, JM; Hatch, KD; Kim, RY; Partridge, EE; Potter, ME; Shingleton, HM; Soong, SJ | 1 |
| Boyes, D; Carmichael, J; Fraser, R; Gerulath, A; Kirk, M; Klaassen, D; Levitt, M; Methot, Y; Shelley, W; Starreveld, A | 1 |
| Bakshi, S; Emrich, LJ; Lele, SB; Parthasarathy, KL; Piver, MS | 1 |
| Askin, F; Currie, J; Fowler, W; Halle, J; Rosenman, J; Varia, M; Venkatraman, S; Walton, L | 1 |
| Burrell, MO; Kirchner, AB; Powell, JL | 1 |
| Bandy, LC; Clarke-Pearson, DL; Creasman, WT; Soper, JT; Wilkinson, RH | 1 |
| Ehrlich, CE; Hornback, NB; Reddy, S; Stehman, FB; Sutton, GP | 1 |
| Flower, MA; Jones, A; McCready, VR; Ott, RJ | 1 |
| Boyes, D; Gerulath, A; Klaassen, D; Levitt, M; Miller, A; Shelly, W; Starreveld, A | 1 |
| Hester, HL; White, L | 1 |
| Julian, CG; Woodruff, JD | 1 |
2 review(s) available for chromium and Ovarian Neoplasms
| Article | Year |
|---|---|
Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
Topics: Adolescent; Adult; Aged; Chromium; Chromium Compounds; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Melphalan; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prospective Studies; Radiotherapy | 1991 |
The role of chemotherapy in the treatment of primary ovarian malignancy.
Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Ascites; Chlorambucil; Chromium; DNA Replication; DNA, Neoplasm; Endometriosis; Female; Gold Isotopes; Humans; Methods; Neoplasm Metastasis; Ovarian Neoplasms; Phosphates; Phosphorus Isotopes; Pregnancy; Teratoma; Vinblastine; Vincristine | 1969 |
6 trial(s) available for chromium and Ovarian Neoplasms
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish | 2023 |
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Topics: Breast Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Chromium; Dendritic Cells; Epitopes; Female; Humans; Ovarian Neoplasms; Peptide Fragments; Receptor, ErbB-2; T-Lymphocytes, Cytotoxic; Tissue Donors; Tumor Cells, Cultured | 2006 |
Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary.
Topics: Adult; Aged; Brachytherapy; Carcinoma; Chromium; Chromium Compounds; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Intestines; Life Tables; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Cavity; Phosphates; Phosphorus Radioisotopes; Radiation Injuries; Reoperation; Survival Analysis | 1992 |
Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
Topics: Adolescent; Adult; Aged; Chromium; Chromium Compounds; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Melphalan; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prospective Studies; Radiotherapy | 1991 |
Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
Topics: Chromium; Chromium Compounds; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Melphalan; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prognosis; Random Allocation | 1988 |
External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report.
Topics: Brachytherapy; Chromium; Chromium Compounds; Female; Humans; Melphalan; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes | 1985 |
28 other study(ies) available for chromium and Ovarian Neoplasms
| Article | Year |
|---|---|
Effect of Interaction between 17β-Estradiol, 2-Methoxyestradiol and 16α-Hydroxyestrone with Chromium (VI) on Ovary Cancer Line SKOV-3: Preliminary Study.
Topics: 2-Methoxyestradiol; Apoptosis; Cell Line, Tumor; Cell Survival; Chromates; Chromium; Drug Antagonism; Drug Synergism; Estradiol; Female; Humans; Hydroxyestrones; Ovarian Neoplasms; Potassium Compounds | 2020 |
Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antigen-Presenting Cells; Ascites; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chromium; Cystadenocarcinoma, Serous; Cytokines; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Flow Cytometry; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate; T-Lymphocytes, Regulatory | 2009 |
Radioactive isotope therapy for ovarian carcinoma. Subsequent pregnancy and intra-abdominal radioactive isotope therapy during pregnancy.
Topics: Chromium; Chromium Radioisotopes; Female; Gold Radioisotopes; Humans; Ovarian Neoplasms; Pregnancy; Radioisotopes | 1961 |
Intraperitoneal chromic phosphate in peritoneoscopically confirmed stage I ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Chromium; Chromium Compounds; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Laparoscopy; Middle Aged; Ovarian Neoplasms; Phosphates; Prognosis; Prospective Studies | 1982 |
Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites.
Topics: Adult; Aged; Ascites; Brachytherapy; Chromium; Chromium Compounds; Female; Humans; Kinetics; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Uterine Neoplasms | 1984 |
Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
Topics: Breast Feeding; Chromium; Chromium Compounds; Cystadenocarcinoma; Female; Humans; Infant, Newborn; Milk, Human; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Radiation Dosage | 1984 |
Radioactivity in breast milk after intraperitoneal chromic phosphate for the treatment of early ovarian cancer.
Topics: Adult; Breast Feeding; Chromium; Chromium Compounds; Cystadenocarcinoma; Female; Humans; Infant, Newborn; Injections, Intraperitoneal; Milk, Human; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Pregnancy; Pregnancy Complications, Neoplastic | 1983 |
Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chromium; Chromium Compounds; Combined Modality Therapy; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prognosis | 1984 |
Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.
Topics: Chromium; Chromium Compounds; Female; Humans; Ovarian Neoplasms; Peritoneal Cavity; Phosphates; Posture; Radionuclide Imaging; Sulfur; Technetium; Technetium Tc 99m Sulfur Colloid; Time Factors; Tissue Distribution | 1983 |
Astatine-211--tellurium radiocolloid cures experimental malignant ascites.
Topics: Alpha Particles; Animals; Ascites; Astatine; Cell Survival; Chromium; Chromium Compounds; Colloids; Female; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Radioisotopes; Tellurium; Transplantation, Homologous | 1981 |
Effects of injection volume on the tissue dose, dose rate, and therapeutic potential intraperitoneal 32p.
Topics: Animals; Autoradiography; Carcinoma; Cell Line; Chromium; Chromium Compounds; Cricetinae; Diaphragm; Dose-Response Relationship, Radiation; Female; Injections, Intraperitoneal; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Radiotherapy Dosage; Rats | 1981 |
Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals.
Topics: Adenocarcinoma; Ascitic Fluid; Chromium; Chromium Compounds; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prognosis; Uterine Cervical Neoplasms; Uterine Neoplasms | 1981 |
Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
Topics: Animals; Autoradiography; Chromium; Female; Injections, Intraperitoneal; Models, Biological; Ovarian Neoplasms; Peritoneum; Phosphates; Phosphorus Radioisotopes; Rabbits; Radiotherapy Dosage; Time Factors; Tissue Distribution | 1980 |
Particle concentration fluorescence immunoassay chemosensitivity assay for human epithelial ovarian cancer.
Topics: Cell Death; Cell Line, Transformed; Chromium; Cisplatin; Drug Screening Assays, Antitumor; Female; Fluorescence Polarization Immunoassay; Humans; Ovarian Neoplasms | 1994 |
DNA binding activity of the mammalian translation elongation complex: recognition of chromium- and transplatin-damaged DNA.
Topics: Amino Acid Sequence; Animals; Carcinoma; Chromium; Cisplatin; Cross-Linking Reagents; DNA Adducts; DNA Damage; DNA-Binding Proteins; Female; Humans; Ligands; Molecular Sequence Data; Neoplasm Proteins; Ovarian Neoplasms; Peptide Elongation Factors; Tumor Cells, Cultured | 1997 |
Calcium-mediated telomerase activity in ovarian epithelial cells.
Topics: Cadmium; Calcium; Cell Transformation, Neoplastic; Cells, Cultured; Chromium; Epithelial Cells; Female; Humans; Ovarian Neoplasms; Telomerase; Tumor Cells, Cultured; Verapamil | 2002 |
Intraperitoneal distribution of 32P-chromic phosphate suspension in the dog.
Topics: Animals; Chromium; Dogs; Female; Lymphatic Metastasis; Neoplasm Metastasis; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphates; Phosphorus Radioisotopes; Radiography; Tissue Distribution | 1979 |
Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Chromium; Chromium Compounds; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phosphates; Survival Analysis | 1992 |
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Topics: Chromium; Chromium Compounds; Combined Modality Therapy; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Retrospective Studies; Survival Analysis | 1991 |
Bowel perforation associated with intraperitoneal chromic phosphate instillation.
Topics: Chromium; Chromium Compounds; Colonic Diseases; Cystadenocarcinoma; Female; Humans; Intestinal Perforation; Middle Aged; Ovarian Neoplasms; Phosphates | 1990 |
Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Topics: Chromium; Chromium Compounds; Female; Humans; Instillation, Drug; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Cavity; Phosphates; Phosphorus Radioisotopes | 1989 |
Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Chromium; Chromium Compounds; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prospective Studies; Time Factors | 1988 |
Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Topics: Carcinoma; Chromium; Chromium Compounds; Female; Humans; Infusions, Parenteral; Laparotomy; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Prognosis; Reoperation | 1988 |
Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
Topics: Adenocarcinoma; Brachytherapy; Chromium; Chromium Compounds; Cystadenocarcinoma; Endometriosis; Female; Humans; Middle Aged; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes | 1987 |
Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Papillary; Chromium; Chromium Compounds; Combined Modality Therapy; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Cavity; Phosphates; Phosphorus Radioisotopes; Reoperation | 1987 |
Ovarian carcinoma: adjuvant treatment with P-32.
Topics: Brachytherapy; Carcinoma; Chromium; Chromium Compounds; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phosphates; Phosphorus Radioisotopes; Posture; Radiotherapy Dosage | 1987 |
The measurement of radiation doses from P32 chromic phosphate therapy of the peritoneum using SPECT.
Topics: Chromium; Chromium Compounds; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Peritoneum; Phosphates; Phosphorus Radioisotopes; Radiation Dosage; Tomography, Emission-Computed | 1985 |
Radioactive colloidal chromic phosphate in the treatment of ovarian malignancies.
Topics: Ascites; Catheterization; Chromium; Colloids; Cystadenocarcinoma; Cystadenoma; Female; Granulosa Cell Tumor; Humans; Neoplasm Seeding; Ovarian Neoplasms; Palliative Care; Phosphorus Isotopes; Radiotherapy; Radiotherapy Dosage | 1969 |